Items where authors include "de Tute, RM"

Export as [feed] Atom [feed] RSS
Number of items: 7.

Article

de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X

Poulter, JA orcid.org/0000-0003-2048-5693, Collins, JC, Cargo, C et al. (12 more authors) (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood. ISSN 0006-4971

Jackson, GH, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (21 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078

Conference or Workshop Item

Cook, G, Pawlyn, C, Royle, K-L et al. (20 more authors) (2021) Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials. In: 63rd American Society of Hematology Annual Meeting, 11-14 Dec 2021, Atlanta, Georgia, USA.

Proceedings Paper

Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.

Cook, G orcid.org/0000-0003-0223-3652, Parrish, C, Yong, K et al. (12 more authors) (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

This list was generated on Mon Mar 25 03:58:13 2024 GMT.